| Ticker: FMRX | 1221 Innsbruck Drive | |
| Exchange: NASDAQ-National Market | Sunnyvale, California 94089 | |
| Industry: Manufacturing | (408) 752-8580 |
| Type of Shares: | Common Shares | Filing Date: | 2/6/96 | |
| U.S. Shares: | 2,700,000 | Offer Date: | 3/27/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,700,000 | Offer Price: | $9.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.63 | |
| Offering Amount: | $32,400,000 | Selling: | $0.36 | |
| Expenses: | $950,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,378,752 |
| Manager | Tier | Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Dillon, Read & Co. Inc. | Co-manager | (212) 906-7000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $2.41 | Assets: | $4.12 | ||
| Net Income: | -$3.17 | Liabilities: | $0.58 | ||
| EPS: | -$0.52 | Equity: | $3.54 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The Company is developing innovative surgical systems for the diagnosis and treatment of gynecologic disorders. The company's initial product, the OPERA STAR System, is designed to perform a procedure the company has named OPERA or Out-Patient Endometrial Resection/Ablation. OPERA is a less invasive alternative to hysterectomy for patients suffering from abnormal uterine bleeding. Abnormal uterine bleeding affects an estimated 9% to 14% of U.S. women over the age of 25 years. The OPERA STAR System consists of a disposable Specialized Tissue Aspirating Resectoscope and reusable motor drive unit. The STAR enables a gynecologic surgeon to cut, coagulate and aspirate tissue within the uterus performing continuous surgery with one instrument without the frequent interruption of clearing the operative field of tissue chips during a procedure as is necessary with other surgical procedures. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund sales and marketing activities, research and development, including clinical trials, and for other general corporate purposes including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.